

## Daratumumab (Darzalex) Rapid Infusion Protocol

### **Criteria for Rapid Infusion**

Patients may receive rapid infusion daratumumab if the following criteria are met:

- Patients received  $\geq 2$  consecutive daratumumab 16 mg/kg doses at standard infusion rate without infusion-related reactions for the doses prior to starting rapid infusion
- Able to tolerate a 500 mL infusion for previous daratumumab infusions

Chemotherapy treatment plan orders will offer the rapid infusion daratumumab option starting at Cycle 2, Day 1

### **Rapid Infusion Rate**

- Ordered for daratumumab (Darzalex) only (not for daratumumab and hyaluronidase (not for Darzalex Faspro))
- Ordered by oncologist within Beacon treatment plan containing daratumumab
  - Treatment plan orders will offer the rapid infusion daratumumab option starting at Cycle 2, Day 1
- Patients who meet criteria for rapid infusion daratumumab will receive:
  - 20% of the dose infused over 30 minutes and the remaining 80% infused over 60 minutes (total administration time of 90 minutes)
  - Pre-Medications (daratumumab infusion begins 30 minutes after premedications)
    - Famotidine 20 mg PO/IV
    - Montelukast 10 mg PO
    - Acetaminophen 650 mg PO
    - Diphenhydramine 25-50 mg IV/PO
    - Methylprednisolone sodium succinate 60-100 mg IV
      - Steroid selection and dose may differ according to chemotherapy regimen
  - Vital signs should be monitored prior to infusion, every 15 minutes for the first hour, and then at the end of the infusion
  - Patients should be observed for signs/symptoms of infusion reactions for 30 minutes after initial accelerated infusion is completed

### **Standard Infusion (for reference only)**

- Week 1 and 2: Infuse at 50 mL/hr for the first hour (if no infusion reaction occurs, may increase rate by 50 mL/hr every hour to a maximum rate of 200 mL/hr)
- Subsequent infusions: Infuse at 100 mL/hr for the first hour (if no infusion reaction occurs, may increase rate by 50 mL/hr every hour to a max rate of 200 mL/hr)

### **References:**

1. Hamadeh S, Arnall J, Kachur E, et al. Rapid Infusion Daratumumab is Safe and Well Tolerated in Clinical Practice. *American Society of Hematology*. 2018;132(1): 2255.
2. Barr H, Dempsey J, Waller A, et al. Ninety-Minute Daratumumab Infusion is Safe in Multiple Myeloma. *Leukemia*. 2018; 32(11): 2495-2518.
3. Gozzetti A, Bacchiarri F, Sammartano V, et al. Long-Term Safety of Rapid Daratumumab Infusions in Multiple Myeloma Patients. *Front Oncol*. 2020; 10: 570187.
4. Hamadeh IS, Reese ES, Arnall JR, et al. Safety and Cost Benefits of the Rapid Daratumumab Infusion Protocol. *Clinical Lymphoma Myeloma and Leukemia*. 2020; 20(8): 526-532.